These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9922630)

  • 1. Pharmaceutical regulation in the single European market.
    Matthews D; Wilson C
    Med Law; 1998; 17(3):401-27. PubMed ID: 9922630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMEA (European Medicines Evaluation Agency) and the new pharmaceutical procedures for Europe.
    Jones K; Jefferys D
    Health Trends; 1994; 26(1):10-3. PubMed ID: 10171959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
    Hwang TJ; Tomasi PA; Bourgeois FT
    PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
    Chin WW; Joos A
    Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the European regulatory approval system.
    Pignatti F; Boone H; Moulon I
    J Ambul Care Manage; 2004; 27(2):89-97. PubMed ID: 15069985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.
    Permanand G; Mossialos E; McKee M
    Clin Med (Lond); 2006; 6(1):87-90. PubMed ID: 16521363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical regulation in the European Community: barriers to single market integration.
    Orzack LH; Kaitin KI; Lasagna L
    J Health Polit Policy Law; 1992; 17(4):847-68. PubMed ID: 1299692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Increased commercial financing of national Medical Product Agencies within the EU].
    Ramel B
    Lakartidningen; 2003 Jan; 100(5):338-9. PubMed ID: 12607381
    [No Abstract]   [Full Text] [Related]  

  • 11. Multi-level governance: The way forward for European illicit drug policy?
    Chatwin C
    Int J Drug Policy; 2007 Dec; 18(6):494-502. PubMed ID: 18061875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future of the European Union regulatory network in the context of the uptake of new medicines.
    Hoebert JM; Irs A; Mantel-Teeuwisse AK; Leufkens HG
    Br J Clin Pharmacol; 2013 Jul; 76(1):1-6. PubMed ID: 23043328
    [No Abstract]   [Full Text] [Related]  

  • 13. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].
    Enzmann H; Schneider C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [European registration of medicines: pros and cons for prescriber and patient].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1997 May; 141(21):1028-33. PubMed ID: 9340558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [European drug policy].
    Sauer F
    Bull Mem Acad R Med Belg; 1993; 148(5-6):207-12; discussion 212-6. PubMed ID: 8142930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
    Enzmann H; Broich K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Data and market exclusivity for pharmaceuticals in the European Community.
    Kingham RF; Castle GH
    Food Drug Law J; 2000; 55(2):209-23. PubMed ID: 12269365
    [No Abstract]   [Full Text] [Related]  

  • 18. Restrictions on import of drugs for personal use within the European single market.
    Mäkinen MM; Rautava PT; Forsström JJ
    Eur J Public Health; 2002 Dec; 12(4):244-8. PubMed ID: 12506498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation.
    Pignatti F; Gravanis I; Herold R; Vamvakas S; Jonsson B; Marty M
    Clin Cancer Res; 2011 Aug; 17(16):5220-5. PubMed ID: 21844037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiopharmaceuticals 1994. Nil desperandum. European Association of Nuclear Medicine Committees on Radiopharmaceuticals and Positron Emission Tomography.
    Cox PH; Meyer GJ
    Eur J Nucl Med; 1995 Jun; 22(6):563-70. PubMed ID: 7556305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.